Development of Chitosan-Coated PLGA-Based Nanoparticles for Improved Oral Olaparib Delivery: In Vitro Characterization, and In Vivo Pharmacokinetic Studies

Olaparib (OLP) is an orally active poly (ADP-ribose) polymerase enzyme inhibitor, approved for treatment the metastatic stage of prostate, pancreatic, breast and ovarian cancer. Due to its low bioavailability, increase in dose frequency required achieve therapeutic benefits, which also results associated toxicity patients. In current study, OLP-loaded (d,l-lactide-co-glycolide) (PLGA) nanoparticles (NPs) (OLP-PLGA NPs) a coating OLP-PLGA NPs with chitosan (CS) (OLP-CS-PLGA were prepared successfully order improve dissolution rate bioavailability. The developed evaluated hydrodynamic particle size (392 ± 5.3 nm), PDI (0.360 0.03), ZP (−26.9 2.1 mV), EE (71.39 5.5%) DL (14.86 1.4%), OLP-CS-PLGA NPs, (622 9.5 (0.321 0.02), (+36.0 1.7 (84.78 6.3%) (11.05 2.6%). vitro release profile both showed sustained pattern. Moreover, pharmacokinetics exhibited 2.0- 4.75-fold bioavailability respectively, compared normal OLP suspension. revealed that could be effective approach sustaining improving OLP.